The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prior evidence suggests that the renin angiotensin system and antihypertensives that inhibit this system play a role in cognitive, central vascular, and endothelial function. Our objective is to conduct a double-blind randomized controlled clinical trial, the antihypertensives and vascular, endothelial, and cognitive function (AVEC), to compare 1 year treatment of 3 antihypertensives (lisinopril, candesartan, or hydrochlorothiazide) in their effect on memory and executive function, cerebral blood flow, and central endothelial function of seniors with hypertension and early objective evidence of executive or memory impairments. METHODS/DESIGN: The overall experimental design of the AVEC trial is a 3-arm double blind randomized controlled clinical trial. A total of 100 community eligible individuals (60 years or older) with hypertension and early cognitive impairment are being recruited from the greater Boston area and randomized to lisinopril, candesartan, or hydrochlorothiazide ("active control") for 12 months. The goal of the intervention is to achieve blood pressure control defined as SBP < 140 mm Hg and DBP < 90 mm Hg. Additional antihypertensives are added to achieve this goal if needed. Eligible participants are those with hypertension, defined as a blood pressure 140/90 mm Hg or greater, early cognitive impairment without dementia defined (10 or less out of 15 on the executive clock draw test or 1 standard deviation below the mean on the immediate memory subtest of the repeatable battery for the assessment of neuropsychological status and Mini-Mental-Status-exam >20 and without clinical diagnosis of dementia or Alzheimer's disease). Individuals who are currently receiving antihypertensives are eligible to participate if the participants and the primary care providers are willing to taper their antihypertensives. Participants undergo cognitive assessment, measurements of cerebral blood flow using Transcranial Doppler, and central endothelial function by measuring changes in cerebral blood flow in response to changes in end tidal carbon dioxide at baseline (off antihypertensives), 6, and 12 months. Our outcomes are change in cognitive function score (executive and memory), cerebral blood flow, and carbon dioxide cerebral vasoreactivity. DISCUSSION: The AVEC trial is the first study to explore impact of antihypertensives in those who are showing early evidence of cognitive difficulties that did not reach the threshold of dementia. Success of this trial will offer new therapeutic application of antihypertensives that inhibit the renin angiotensin system and new insights in the role of this system in aging. TRIAL REGISTRATION: Clinicaltrials.gov NCT00605072.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Hypertension · doi:10.1161/01.hyp.0000150859.47929.8e · Cited by 2,051
Cardiovascular risk factors and cognitive decline in middle-aged adults
Knopman, D., Boland, L. L., Mosley, T., Howard, G., Liao, D., Szklo, M., McGovern, P., & Folsom, A. R. (2001) · Neurology · doi:10.1212/wnl.56.1.42 · Cited by 883 · cited 1×
“Background In addition to its role in developing cardiovascular disease and stroke, hypertension is also a risk factor for cognitive impairment [1-5] Although blood pressure tends to decline around the time of onset of clinical cognitive impairment[3], hypertension leads to accelerated decline in those with cognitive…”
BackgroundCerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study
Ruitenberg, A., den Heijer, T., Bakker, S. L. M., van Swieten, J. C., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20493 · Cited by 733
Hypertension Is Related to Cognitive Impairment: A 20-Year Follow-up of 999 Men
Kilander, L., Nyman, H., Boberg, M., Hansson, L., & Lithell, H. (1998) · Hypertension · doi:10.1161/01.hyp.31.3.780 · Cited by 630
Incidence and Characteristics of Angioedema Associated With Enalapril
Kostis, J. B., Kim, H. J., Rusnak, J., Casale, T., Kaplan, A., Corren, J., & Levy, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1637 · Cited by 291 · cited 12×
“In addition to their effect on cognitive function, animal and human studies have suggested that both ACEI and ARB are associated with improved cerebral hemodynamics[56,57] In spontaneously hypertensive rats, treatment with ARB was associated with improved cerebral autoregulation[58], reduction in CBF decline after mid…”
InfluentialDi Bari, M., Pahor, M., Franse, L. V., Shorr, R. I., Wan, J. Y., Ferrucci, L., Somes, G. W., & Applegate, W. B. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.1.72 · Cited by 193
Captopril and Enalapril Improve Cognition and Depressed Mood in Hypertensive Patients
Braszko, Karwowska-Polecka, Halicka, & Gard (2003) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.2003.14.4.323 · Cited by 89 · cited 1×
“ACEI block ACE and decrease Ang II production, whereas ARB block the angiotensin receptor type 1 but not type 2[43,44] ACEI and ARB may be protective against cognitive and physical impairment in hypertensives [45-50] In an observational study of 1,220 Italian individuals with heart failure, treatment with ACEI was ass…”
BackgroundWilms, H., Rosenstiel, P., Unger, T., Deuschl, G., & Lucius, R. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505040-00004 · Cited by 52
Moriwaki, H., Uno, H., Nagakane, Y., Hayashida, K., Miyashita, K., & Naritomi, H. (2004) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001735 · Cited by 36
Cited by
Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty
Cosarderelioglu, C., Nidadavolu, L. S., George, C. J., Oh, E. S., Bennett, D. A., Walston, J. D., & Abadir, P. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.586314 · Cited by 134
Hajjar, I., Hart, M., Chen, Y.-L., Mack, W., Milberg, W., Chui, H., & Lipsitz, L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1391 · Cited by 84
Self-citationCunningham, E. L., Todd, S. A., Passmore, P., Bullock, R., & McGuinness, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub4 · Cited by 45
First-line diuretics versus other classes of antihypertensive drugs for hypertension
Reinhart, M., Puil, L., Salzwedel, D. M., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008161.pub3 · Cited by 38
Kehoe, P. G., Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170101 · Cited by 35
Metadata
- Authors
- Hajjar, I., Hart, M., Milberg, W., Novak, V., & Lipsitz, L.
- Venue
- BMC Geriatrics
- Published
- 2009-11-18
- Volume
- 9
- Issue
- 1
- Pages
- 48-48
- ISSN
- 1471-2318 (ISSN-L)
- OpenAlex
- W2122355137
- Cited by
- 35
- References
- 11
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition. https://app.cochat.ai/papers/10.1186/1471-2318-9-48
- The paper
- Hajjar, I., Hart, M., Milberg, W., Novak, V., & Lipsitz, L. (2009). The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition. BMC Geriatrics. https://doi.org/10.1186/1471-2318-9-48
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.